<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942615</url>
  </required_header>
  <id_info>
    <org_study_id>Cardio-RT</org_study_id>
    <nct_id>NCT02942615</nct_id>
  </id_info>
  <brief_title>The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.</brief_title>
  <official_title>A Randomized Multi-center Phase III Study About the Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to explore the optimal strategies for guaranteeing the cardiac safety of breast
      cancer patients following adjuvant radiotherapy in the modern era of multidisciplinary
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the development of modern radiotherapy techniques, the dose-volume of heart irradiated
      could be kept in much low level. However, until now, the optimal dose-volume parameters for
      limiting heart irradiation, the optimal follow-up interval for cardiac safety after adjuvant
      radiotherapy, the optimal screening examinations and treatments for irradiation-induced
      cardiac toxicity are unclear. We designed this trial to find answer for above questions to
      establish rationalization proposal for prevention, treatment and follow-up for cardiac
      toxicity associated with adjuvant radiotherapy for breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac toxicity event free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The time from the date of randomization to any recurrence of clinical or subclinical cardiac toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac toxicity event free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the date of randomization to any recurrence of clinical or subclinical cardiac toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac toxicity event free survival</measure>
    <time_frame>10 years</time_frame>
    <description>The time from the date of randomization to any recurrence of clinical or subclinical cardiac toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>The time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of creatine kinase (CK)-MB</measure>
    <time_frame>1 year</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of Cardiac troponin (cTn)-I</measure>
    <time_frame>1 year</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of N-terminal pro brain natriuretic peptide (NT-proBNP)</measure>
    <time_frame>1 year</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of CK-MB</measure>
    <time_frame>5 years</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of cTn-I</measure>
    <time_frame>5 years</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarkers of NT-proBNP</measure>
    <time_frame>5 years</time_frame>
    <description>The change of value of serum cardiac biomarkers during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of left ventricular ejection fraction (LVEF)</measure>
    <time_frame>1 year</time_frame>
    <description>The change of value of LVEF during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of LVEF</measure>
    <time_frame>5 year</time_frame>
    <description>The change of value of LVEF during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapyThe change of value of LVEF during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of LVEF</measure>
    <time_frame>10 year</time_frame>
    <description>The change of value of LVEF during and after adjuvant radiotherapy compared with baseline before initiation of adjuvant radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life-EORTC QLQ-C30</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life-EORTC QLQ-BR23</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life will be assessed using self-administered questionnaire EORTC QLQ-BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life-EORTC QLQ-C30</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life will be assessed using self-administered questionnaire EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life-EORTC QLQ-BR23</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life will be assessed using self-administered questionnaire EORTC QLQ-BR23</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Heart safety management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>limit heart dose</intervention_name>
    <description>limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%</description>
    <arm_group_label>Heart safety management</arm_group_label>
    <other_name>frequently follow of cardiac function</other_name>
    <other_name>management of cardiotoxicity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to participate the research and sign the informed consent file;

          -  Patients aged 18-80 years;

          -  KPS≥70;

          -  Pathological diagnosis for invasive breast cancer;

          -  Patients received anthracycline/paclitaxel based chemotherapy, or herceptin based
             targeted therapy;

          -  No functional heart disease;

          -  LVEF≥50%;

          -  Patients received breast conserving surgery;

          -  Patients received modified radical mastectomy: T1-2 with N1-3 or T3-4 with any N;

          -  Tumor margin negative;

          -  No metastases;

          -  No other malignant tumor history.

        Exclusion Criteria:

          -  Patients with metastases;

          -  Tumor margin positive;

          -  Patients received modified radical mastectomy with T1-2 and N0;

          -  Patients have other malignant tumor;

          -  Patients have a history of heart disease;

          -  Patients received chest radiotherapy previously;

          -  Patients with severe organic and functional disease;

          -  Unqualified patients with sufficient reasons;

          -  Cannot or no willing to sign the informed consent file;

          -  Patients with autoimmune disease;

          -  Women with pregnancy, planned pregnancy or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia-Yi Chen, M.D.</last_name>
    <phone>+86-021-64370045</phone>
    <phone_ext>602400</phone_ext>
    <email>chenjiayi0188@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia-Yi Chen, M.D.</last_name>
      <phone>+86-021-64370045</phone>
      <phone_ext>602400</phone_ext>
      <email>chenjiayi0188@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia-Yi Chen, M.D</last_name>
      <phone>+86-021-64370045</phone>
      <phone_ext>602400</phone_ext>
      <email>chenjiayi0188@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jiayi Chen</investigator_full_name>
    <investigator_title>Chief of department of radiation oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

